Bioactive Products
| A unique collection of 223 Neuroprotection natural compounds for high throughput screening (HTS) | ||
| Catalog No: | B72a21 | Neuroprotection Compound Library Screening Details |
| Size: | 1mg/well * 223 Compounds 2mg/well * 223 Compounds | |
| Cat. No. | Information |
| CFN99959 | Huperzine A Huperzine A is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).Huperzine A induces CYP3A4 expression and activation via PXR dependent pathways, may contribute to drug-drug interactions with ligustrazine and oridonin. |
| CFN98039 | Cannabichromene Cannabichromene is a major non-psychotropic phytocannabinoid that inhibits endocannabinoid inactivation and activates the transient receptor potential ankyrin-1 (TRPA1), it selectively reduces inflammation-induced hypermotility in vivo in a manner that is not dependent on cannabinoid receptors or TRPA1; it can raise the viability of neural stem progenitor cells (NSPCs), while inhibiting their differentiation into astroglia, possibly through up-regulation of ATP and adenosine signalling. Cannabichromene exerts anti-inflammatory actions in activated macrophages with tonic CB1 cannabinoid signalling being negatively coupled to this effect and ameliorates experimental murine colitis. |
| CFN99963 | Pseudoginsenoside F11 Pseudoginsenoside F11, a novel partial PPAR γ agonist, can promote adiponectin oligomerization and secretion in 3T3-L1 adipocytes and inhibit obesity-linked phosphorylation of PPAR γ at Ser-273 by Cdk5. It possesses significant neuroprotective activity, has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice; it also antagonizes the development of analgesia tolerance to morphine and blocks the development of morphine-induced behavioral sensitization via its effect, at least partially, on the glutamatergic system in the mPFC. |
| CFN99964 | Ginsenoside Rb1 Ginsenoside Rb1 is a protopanaxadiol that has diverse in vitro and in vivo effects, including neuroprotective, cardioprotective, anti-obesity, anti-inflammatory, and anti-oxidative actions. Ginsenoside Rb1 can up-regulate the expression of GLUTs in adipose tissue, in addition to activate insulin signalling pathway, and may effectively ameliorate the progression of asthma through Relegating Th1/Th2. It inhibited Na+, K+-ATPase activity with an IC50 of 6.3±1.0 μM, activated Akt, phosphorylating GSK-3β and inhibited mPTP opening. |
| CFN99966 | Ginsenoside Rb3 Ginsenoside Rb3 has anti-myocardial ischemia-reperfusion injury, neuroprotective, antidepressant-like, and antioxidant effects, it also possesses the potential of the clinical use in preventing and treating diabetes. Ginsenoside Rb3 significantly attenuates the changes of creatine kinase activity and lactate dehydrogenase activity, exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC50 of 8.2 μM in 293T cell lines, it also inhibits the induction of COX-2 and iNOS mRNA. |
